Johnson & Johnson (JNJ) FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
ADVERTISEMENT
Johnson & Johnson (JNJ) Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Q1 2026 Earnings Announcement
Johnson & Johnson (NYSE: JNJ) Q1 2026 Earnings Announcement
Johnson & Johnson (JNJ) Q1 2026 Earnings Call
Johnson & Johnson (NYSE: JNJ) Q1 2026 Earnings Conference
Johnson & Johnson (JNJ) TD Cowen 46th Annual Health Care Conference
Johnson & Johnson (NYSE: JNJ) FY 2026 Corporate Conference
ADVERTISEMENT
Johnson & Johnson (JNJ) Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release